Gyre Therapeutics (formerly known as Catalyst Biosciences) is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases. The Company uses a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. Engineered proteases can efficiently initiate or regulate protease-driven biological cascades and can act on hundreds to thousands of target molecules.